UPMC Ovarian Cancer Study

Cancer differentiation analysis technology as a novel technology for cerebral cancer screening.

In this retrospective, blinded validation study, a mixed cohort of at least 40 banked, frozen human serum samples, consisting of at least 20 samples from cancer free women (controls) and at least 20 samples from ovarian cancer patients (Stage I – IV), will be analyzed with Cancer Differentiation Analysis (CDA) technology for cellular and molecular signals of ovarian cancer. Specifically, this study aims to evaluate the sensitivity and specificity of CDA technology in ovarian cancer screening within a well-defined sample population.
Risk-assessment of all serum samples by Anpac will involve the evaluation of three parameters: Protein Tumor Factor (PTF), Cellular Tumor Factor (CTF), and an overall CDA value.

Details of the work:

1. Dr. Modugno will provide 1mL of frozen serum on each of at least 20 women diagnosed with ovarian cancer and at least 20 control women known to be cancer free at the time of serum collection. The serum samples will be shipped according to Anpac instruction to their lab in San Jose, California.
a. Anpac will pay the cost of shipping.
b. Samples will be labeled only with a study ID. No identifying information will ever be provided to Anpac.
c. The key linking study ID to patient name will be maintained by Dr. Modugno and her staff and will at no time be shared with Anpac or other study investigators at the University of Pittsburgh.
2. Within six months of receipt of the samples, Anpac will provide to Dr. Modugno with the data elements for each sample, including PTF, CTF and overall CDA values.
3. A member of Dr. Modugno’s study team will analyze the data.
a. A Receiver-operator curve (ROC) will be employed to evaluate the accuracy of CDA technology in ovarian cancer screening within the study population.
4. The resulting ROC will be provided back to Anpac

R&D investigations and formal clinical trials in the United States.

Additional Clinical Trials

iMarc Breast Cancer Research

iMarc Breast Cancer Research

Anpac Bio’s CDA, Cancer Differentiation Analysis, is a revolutionary technology.

Results speak.

26

Cancer types detected

525+

screened cases

85-90%

Accuracy rate

200k+

Test samples run to date

“game changing”

CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article
©2019 Anpac Bio-Medical Science Co., Ltd.
;